Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
-$0.08 today
- Market cap
- $61.80M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
Volume 0.01M
Average 0.01M
CSBR Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Champions Oncology, Inc.NASDAQ: CSBR
Depreciation & Amortization · Q3 FY2026 · quarter ended Jan 2026
Depreciation & amortization declines year over year
Q3 FY2026 depreciation & amortization of $341K fell 14.3% year over year, ahead of the -14.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at +0.3% a year.
Context
- Depreciation & amortization amounted to 2.9% of revenue in FY2025, down 0.8 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -14.3% holds above the trailing-twelve-month pace of -14.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.64M USD
- Year-over-year change
- -12.2%
- 4-year CAGR
- +8.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 1.64M | -12.2% |
| FY2024 | 2024-04-30 | 1.87M | -16.9% |
| FY2023 | 2023-04-30 | 2.25M | +38.0% |
| FY2022 | 2022-04-30 | 1.63M | +37.4% |
| FY2021 | 2021-04-30 | 1.18M | — |
Depreciation & Amortization vs competitors
How CSBR compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -14.9% is the 6th highest of 9, against a peer median of -6.4%.
- Depreciation & amortization amounts to 2.5% of revenue for CSBR, versus a peer median of 364.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.7M USD | -8.9% | +8.8% | 6.7% | |
| LTM Mar 2026 | $3.64M USD | -3.9% | +6.3% | 364.3% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.71M USD | +9.6% | +30.9% | — |
| LTM Jan 2026 | $1.45M USD | -14.9% | +0.3% | 2.5% | |
| FY2025 | $704K USD | +6.7% | -11.4% | 1100.0% | |
IMAImageneBio Inc | LTM Mar 2026 | $616K USD | +72.1% | -24.1% | — |
| LTM Mar 2026 | €377.74K EUR | -20.5% | -12.3% | 1287.9% | |
| LTM Mar 2026 | $175K USD | -96.8% | -25.1% | 0.8% | |
| LTM Mar 2026 | $121K USD | -27.5% | +27.8% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $20K USD | — | — | — |
| Peer median (excluding CSBR) | — | -6.4% | -2.6% | 364.3% | |
Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Apr 2021 | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Net Income | 334K | 548K | (5.34M) | (7.28M) | 4.7M |
| Depreciation & Amortization | 1.18M | 1.63M | 2.25M | 1.87M | 1.64M |
| Deferred Income Tax | 49K | 0 | 1M | 0 | 0 |
| Stock-Based Compensation | 598K | 912K | 864K | 1.12M | 654K |
| Change in Working Capital | (4.17M) | 2.34M | 4.23M | (3.82M) | (621K) |
| Accounts Receivables | (2.27M) | (2.82M) | 1.31M | (1.99M) | (1.44M) |
| Inventory | (1.1M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.25M) | 974K | 2.47M | 465K | (1.75M) |
| Other Working Capital | 441K | 4.18M | 470K | (2.3M) | 2.56M |
| Other Non-Cash Items | 323K | 1.07M | 952K | 1.98M | 1.01M |
| Operating Cash Flow | (1.68M) | 6.5M | 3.96M | (6.14M) | 7.39M |
| Capital Expenditures | (3.28M) | (2.38M) | (2.87M) | (836K) | (389K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 112K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.17M) | (2.38M) | (2.87M) | (836K) | (389K) |
| Debt Repayment | (174K) | 0 | 0 | (146K) | (150K) |
| Common Stock Issued | 1.37M | 207K | 85K | 253K | 320K |
| Common Stock Repurchased | 0 | 0 | (74K) | (634K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 85K | 253K | 0 |
| Financing Cash Flow | 1.2M | 207K | 11K | (527K) | 170K |
| Effect of Forex Changes | 0 | 0 | 17K | 0 | 0 |
| Net Change in Cash | (3.66M) | 4.32M | 1.11M | (7.5M) | 7.17M |
| Free Cash Flow | (4.96M) | 4.11M | 1.08M | (6.97M) | 7M |
Champions Oncology, Inc.
NASDAQ:CSBR
Intrinsic Alpha fair value
Locked
Current Price
$4.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.